Abstract
Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and Crohns disease have an increased atherosclerotic risk which cannot be explained by traditional cardiovascular risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The involvement of cytokine – related signaling pathways in inflammatory diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progression. Whether modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis remains unknown. In this review we will focus on the role of pro-inflammatory cytokines and their inhibitors in RA, and whether they may be causal in the accelerated atherosclerosis seen in these patients.
Keywords: Rheumatoid arthritis, cytokine, inflammation, atherosclerosis, anti-microbial and anti-fungicidal properties, L tryptophane, in-dole glucosinolates, alkenyl glucosinolates, bio-fumigants, 2, –, oxazolidimethione, N, hydroxy-amino acid, aldoxime, hydroxy acid, de-sulpho glucosinolate, Moringaceae
Current Pharmaceutical Design
Title: Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation
Volume: 17 Issue: 1
Author(s): Ashley M. Miller and Iain B. McInnes
Affiliation:
Keywords: Rheumatoid arthritis, cytokine, inflammation, atherosclerosis, anti-microbial and anti-fungicidal properties, L tryptophane, in-dole glucosinolates, alkenyl glucosinolates, bio-fumigants, 2, –, oxazolidimethione, N, hydroxy-amino acid, aldoxime, hydroxy acid, de-sulpho glucosinolate, Moringaceae
Abstract: Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and Crohns disease have an increased atherosclerotic risk which cannot be explained by traditional cardiovascular risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The involvement of cytokine – related signaling pathways in inflammatory diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progression. Whether modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis remains unknown. In this review we will focus on the role of pro-inflammatory cytokines and their inhibitors in RA, and whether they may be causal in the accelerated atherosclerosis seen in these patients.
Export Options
About this article
Cite this article as:
M. Miller Ashley and B. McInnes Iain, Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation, Current Pharmaceutical Design 2011; 17 (1) . https://dx.doi.org/10.2174/138161211795049796
DOI https://dx.doi.org/10.2174/138161211795049796 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Oxidative Stress in Atherosclerosis Development: The Central Role of LDL and Oxidative Burst
Endocrine, Metabolic & Immune Disorders - Drug Targets Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Current Vascular Pharmacology The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry Coronary Microcirculation and Ischemic Heart Disease, Today
Current Pharmaceutical Design Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets An Efficient Immobilization of Cholesterol Oxidase from Bacillus sp. COX-T<sub>3</sub> onto Psyllium Husk Fibers
Current Biotechnology Proteomic Analysis of Liver Diseases: Molecular Mechanisms and Biomarker Discovery
Mini-Reviews in Medicinal Chemistry The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]
Current Vascular Pharmacology New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism Mitochondrial Oxidative Stress and Heart Failure ∼Novel Pathophysiological Insight and Treatment Strategies∼
Current Cardiology Reviews